Guardant Health (NASDAQ:GH) CTO Sells $567,122.04 in Stock

Guardant Health, Inc. (NASDAQ:GH) CTO Darya Chudova sold 5,451 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $104.04, for a total value of $567,122.04. Following the completion of the transaction, the chief technology officer directly owned 7,012 shares in the company, valued at $729,528.48. This trade represents a 43.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Darya Chudova also recently made the following trade(s):

• On Monday, December 8th, Darya Chudova sold 13,664 shares of Guardant Health stock. The shares were sold at an average price of $105.04, for a total value of $1,435,266.56.
• On Monday, December 8th, Darya Chudova sold 9,271 shares of Guardant Health stock. The stock was sold at an average price of $106.00, for a total transaction of $982,726.00.

Guardant Health Trading Down 2.5%

GH stock traded down $2.53 during midday trading on Wednesday, reaching $97.47. 1,912,147 shares of the company’s stock traded hands, compared to its average volume of 2,452,903. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43. The stock has a market cap of $12.29 billion, a P/E ratio of -30.36 and a beta of 1.58. The stock’s 50-day moving average is $90.23 and its 200 day moving average is $66.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same period in the previous year, the business earned ($0.88) earnings per share. The company’s quarterly revenue was up 38.5% compared to the same quarter last year. As a group, research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Several institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers purchased a new stake in shares of Guardant Health during the 1st quarter worth approximately $211,000. PNC Financial Services Group Inc. increased its position in Guardant Health by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock worth $112,000 after purchasing an additional 537 shares during the last quarter. Nuveen LLC purchased a new stake in Guardant Health during the first quarter valued at $3,151,000. HighTower Advisors LLC lifted its position in Guardant Health by 0.9% during the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after purchasing an additional 469 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Guardant Health by 0.3% during the first quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after purchasing an additional 282 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Leerink Partners increased their price target on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a research note on Monday. Wells Fargo & Company increased their target price on Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. Finally, Piper Sandler upped their price target on Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Twenty-three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.52.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.